P126 Pathological complete response after neoadjuvant chemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) – experience from Institute for Oncology and Radiology of Serbia (IORS)
Main Authors: | O. Djurmez, M. Calamac, N. Stanic, M. Dimitrijevic, J. Vukosavljevic, K. Serovic, J. Oblakovic-Babic, I. Minic, D. Gavrilovic, I. Bozovic-Spasojevic |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Breast |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977623002436 |
Similar Items
-
P288 Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?
by: M. Calamac, et al.
Published: (2023-03-01) -
Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
by: Ashok Vaid, et al.
Published: (2022-04-01) -
Long-Term eBC Measurements with the Use of MAAP in the Polluted Urban Atmosphere (Poland)
by: Natalia Zioła, et al.
Published: (2021-06-01) -
Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01) -
Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)